Oral presentations
| 8. |
Phosphomimetic lipopeptides as new tools to investigate β-arrestin-mediated functions. |
|
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec – October 19th-21st, 2017 (Ottawa, Canada.) |
| 7. |
Phosphomimetic lipopeptides as new tools to investigate β-arrestin-mediated functions. |
|
Journée Phare 2016 – December 1st-2nd, 2016 (Bromont, Canada.) |
| 6. |
Phosphomimetic lipopeptides as new tools to investigate β-arrestin-mediated functions. |
|
Neuroscience 2016 – 46th Annual Meeting of the Society for Neuroscience – November 12th-16th, 2016 (San Diego, USA.) |
| 5. |
β-arrestin-2-biased apelin receptor agonists as novel potent analgesics. |
|
Symposium of the Pain and Inflammation research axis of the Université de Sherbrooke – November 2nd, 2016 (Sherbrooke, Canada.) |
| 4. |
New biased analogs of Apelin-13 and their impacts on cardiovascular effects. |
|
5th Montpellier-Sherbrooke Symposium – June 11th, 2015 (Sherbrooke, Canada.) |
| 3. |
Molecular Signature of the Neurotensin Receptor 1. |
|
3rd Scientific day of Quebec Drug Research Network – September 18th-19th, 2013 (Montreal, Canada) |
| 2. |
BRET-Based Assay Development for the Discovery of Novel GPCR Ligands. |
|
Journée Phare 2012 – November 16th, 2012 (Orford, Canada) |
| 1. |
BRET-Based Assay Development for the Discovery of Novel GPCR Ligands. |
|
Conference of the Sherbrooke Institute of Pharmacology – October 25th, 2012 (Sherbrooke, Canada)
|
Poster presentations at international conferences
(* denotes presenting author)
| 47. |
Tiffinger A., *Besserer-Offroy É., Côté J., Coquerel D., Murza A., Longpré J.M., Auger-Messier M., Lesur O., Marsault E., Dumaine R. and Sarret P. |
|
Effects of C-terminally-modified apelin-13 analogs on cardiovascular function |
|
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada. |
| 46. |
*Nepveu-Traversy M.E., Morissette S., Boudreault P.L., Besserer-Offroy É., Kirby K., Longpré J.M., Gendron F.P., Breton B., Marsault E., Gaudreau S, and Sarret P. |
|
Chicken antibodies engineered to target the 3D structure of extracellular loops of GPCRs |
|
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada. |
| 45. |
*Midavaine E., Brouillette R., Besserer-Offroy É., Mona C., Jacobi A., Rose S., Belkhe M., Longpré J.M. and Sarret P. |
|
Targeting the CCL-CCR2 chemokine axis in bone cancer pain: Uncovering analgesic efficacy using non-classical pharmacological approaches |
|
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada. |
| 44. |
*Brouillette R., Besserer-Offroy É., Mona C., Lavenus S., Côté J., Soubie M., Longpré J.M., Leduc R., Grandbois M., Marsault E. and Sarret P. |
|
Allosteric modulation of the neurotensin 1 receptor by a series of cell-penetrating pepducins targeting the first intracellular loop |
|
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada. |
| 43. |
*Vivancos M., Fanelli R., Orliaguet M., Floquet N., Côté J., Besserer-Offroy É., Murza A., Longpré J.M., Thomas, J.B., Martinez J., Cavelier F. and Sarret P. |
|
Preferentially targeting the NTS2 receptor: a promising avenue for the development of new neurotensinergic analgesic compounds |
|
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada. |
| 42. |
*Mona C., Besserer-Offroy É., Cabana J., Leduc R., Lavigne P., Heveker N., Marsault É. and Escher E. |
|
Design, Synthesis, and Biological Evaluation of CXCR4 Ligands |
|
25th American Peptide Symposium; June 17th-22th, 2017; Whistler, Canada. |
| 41. |
*Sousbie M., Besserer-Offroy É., Brouillette R., Longpré J.M., Sarret P., Leduc R. and Marsault E. |
|
Rational design of neurotensin 8-13 macrocyclic peptidic analogues. Conformational investigation and hit discovery |
|
25th American Peptide Symposium; June 17th-22th, 2017; Whistler, Canada. |
| 40. |
*Nepveu-Traversy M.E., Morissette S., Boudreault P.L., Besserer-Offroy É., Kirby K., Longpré J.M., Gendron F.P., Breton B., Marsault E., Gaudreau S, and Sarret P. |
|
Characterization of chicken antibodies targeting the 3D structure of the second extracellular loop of the neurotensin receptor type 1 |
|
14th Annual Protein and Antibody Engineering Summit, PEGS; May 1st-4th, 2017; Boston, USA. |
| 39. |
*Côté J., Besserer-Offroy É., Murza A., Belleville K., Eiselt E., Larocque A., Régina A., Longpré J.M., Demeule M. and Sarret P. |
|
Improving blood-brain barrier penetration to convert neurotensin bioactive peptides into painkillers |
|
Neuroscience 2016 (46th Annual Meeting of the Society for Neuroscience); November 12th-16th, 2016; San Diego, USA. |
|
[Online Abstract] |
| 38. |
*Brouillette R., Mona C., Besserer-Offroy É., Lavenus S., Côté J., Sousbie M., Longpré J.M.*, Leduc R., Grandbois M., Marsault E. and Sarret P. |
|
Deciphering the cellular and physiological actions of cell-penetrating pepducins affecting NTS1 signaling |
|
Neuroscience 2016 (46th Annual Meeting of the Society for Neuroscience); November 12th-16th, 2016; San Diego, USA. |
|
[Online Abstract] |
| 37. |
*Vivancos M., Fanelli R., Orliaguet M., Côté J., Besserer-Offroy É., Murza A., Longpré J.M., Thomas, J.B., Martinez J., Cavelier F. and Sarret P. |
|
Characterization of new stable NTS2-selective neurotensin analogs |
|
Neuroscience 2016 (46th Annual Meeting of the Society for Neuroscience); November 12th-16th, 2016; San Diego, USA. |
|
[Online Abstract] |
| 36. |
*Sousbie M., Besserer-Offroy É., Longpré J.M., Sarret P., Leduc R. and Marsault E. |
|
Rational design of neurotensin 8-13 macrocyclic peptidic analogues. Conformational investigation and hit discovery |
|
17th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 13th-15th, 2016; Chicago, USA. |
| 35. |
*Murza A., Sainsily X., Coquerel D., Côté J., Marx, P., Besserer-Offroy É., Longpré J.M., Lesur O., Auger-Messier M., Sarret P. and Marsault E. |
|
Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions |
|
17th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 13th-15th, 2016; Chicago, USA. |
| 34. |
Mona C., Besserer-Offroy É., Cabana J., Leduc R., Lavigne P., Heveker N., Marsault É. and *Escher E. |
|
Agonists-antagonist transition in CXCR4 ligands |
|
Annual Meeting of the Canadian Society of Pharmacology and Therapeutics; September 19th-21st, 2016; Vancouver, Canada. |
| 33. |
*Fanelli. R., Floquet N., Vivancos M., Delort B., Besserer-Offroy É., Longpré J.M., Martinez J., Sarret P and Cavelier F. |
|
NTS1 and NTS2 diversity delineated by molecular modeling drives the synthesis of new selective neurotensin analogues |
|
34th European Peptide Symposium; September 4th-9th, 2016; Leipzig, Germany. |
| 32. |
*Cavelier F., Fanelli R., Floquet N., Vivancos M., Besserer-Offroy É., Longpré J.M., Martinez J., and Sarret P. |
|
Molecular modeling, design, and synthesis of new NTS2-selective neurotensin analogues |
|
International Symposium on Regulatory Peptides; July 11th-16th, 2016; Rouen, France. |
| 31. |
*Marsault E., Besserer-Offroy É., Bérubé P., Côté J., Murza A., Longpré J.M., Leduc R., Coquerel D., Dumaine R., Auger-Messier M. and Lesur O and Sarret P. |
|
Molecular engineering of apelin to modulate stability, signaling, and cardiovascular functions |
|
International Symposium on Regulatory Peptides; July 11th-16th, 2016; Rouen, France. |
| 30. |
*Besserer-Offroy É., Bérubé P., Côté J., Murza A., Longpré J.M., Leduc R., Marsault E., and Sarret P. |
|
C-terminal modifications of apelin-13 lead to β-arrestin-biased analogs lowering blood pressure |
|
29th Annual Canadian Student Health Research Forum; June 7th-9th, 2016; Winnipeg, Canada. |
| 29. |
*Marsault E., Murza A., Trân K., Sainsily X., Côté J., Besserer-Offroy É., Longpré J.M., Sarret P., Coquerel D., Dumaine R., Auger-Messier M., and Lesur O. |
|
Modulating the structure of apelin to bias signaling of the APJ receptor: impact and potential in cardiovascular diseases |
|
99th Canadian Chemistry Conference and Exhibition; June 5th-9th, 2016; Halifax, Canada. |
| 28. |
*Marsault E., Murza A., Besserer-Offroy É., Côté J., Longpré J.M. and Sarret P. |
|
Modulating the apelin receptor signaling with macrocycles |
|
Pacifichem; December 15th-20th, 2015; Honolulu, HI, USA. |
| 27. |
*Lavenus S., Besserer-Offroy É., Simard É., Leduc R. and Grandbois M. |
|
In depth profiling of AT1 signaling using cell-based and label free surface plasmon resonance: major implication of Gq-independent pathways in cell response |
|
16th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 22nd-24th, 2015; Orangeville, Canada. |
| 26. |
*Sousbie M., Besserer-Offroy É., Longpré J.M., Sarret P., Leduc R. and Marsault É. |
|
Macrocyclic analogues of Neurotensin 8-13: effect of conformational restriction on ligand binding and signaling |
|
16th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 22nd-24th, 2015; Orangeville, Canada. |
| 25. |
*Besserer-Offroy É., Lafrance M., Ouirzane M., Murza A., Longpré J.M., Marsault E., Leduc R., and Sarret P. |
|
β-arrestin-2-biased apelin receptor agonists as novel potent analgesics |
|
Neurosciences 2015 (45th annual meeting of the Society for Neuroscience) October 17th-21st, 2015; Chicago, IL, USA. |
|
[Online Abstract] |
| 24. |
*Vivancos M., Besserer-Offroy É., Brouillette R., René A., Fanelli R., Lafrance M., Tétreault P., Colerette-Tremblay J., Longpré J.M., Martinez J., Cavelier F. and Sarret P. |
|
Site-selective modifications of the neurotensin hexapeptide fragment lead to the generation of highly active and metabolically stable NT(8-13) analogs |
|
Neurosciences 2015 (45th annual meeting of the Society for Neuroscience) October 17th-21st, 2015; Chicago, IL, USA. |
|
[Online Abstract] |
| 23. |
*Sousbie M., Besserer-Offroy É., Longpré J.M., Sarret P., Leduc R. and Marsault É. |
|
Macrocyclic analogues of Neurotensin 8-13: effect of conformational restriction on ligand binding and signaling |
|
24th American Peptide Symposium; June 20th-25th, 2015; Orlando, FL, USA. |
| 22. |
*Mona C., Lefrançois M., Besserer-Offroy É., Leduc R., Heveker N., Marsault É. and Escher E. |
|
CXCR4-induced chemotaxis is not β-arrestin mediated, evidence from synthetic CXCR4 agonists |
|
24th American Peptide Symposium; June 20th-25th, 2015; Orlando, FL, USA. |
| 21. |
*Sousbie M., Besserer-Offroy É., Longpré J.M., Sarret P., Leduc R. and Marsault É. |
|
Macrocyclic analogues of Neurotensin 8-13: effect of conformational restriction on ligand binding and signaling |
|
98th Canadian Chemistry Conference and Exhibition; June 13th-17th, 2015; Ottawa, Canada. |
|
[Online Abstract Booklet] |
| 20. |
*Besserer-Offroy É., Brumwell A., Murza A., Longpré J.M., Sarret P. and Leduc R. |
|
Establishing the signaling signature of hNTS1 engaged following endogenous neurotensin-like peptide stimulation |
|
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada. |
| 19. |
*Besserer-Offroy É., Murza A., Bérubé P., Dinh T., Longpré J.M., Leduc R., Marsault É. and Sarret P. |
|
C-terminal modifications of Apelin-13: generation of new biased analogs and impact on hypotensive effect |
|
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada. |
| 18. |
*Murza A., Besserer-Offroy É., Bérubé P., Longpré J.M., Sarret P. and Marsault E. |
|
Design, synthesis and exploration of structure-function relationship studies of new macrocyclic derivatives of apelin-13 |
|
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada. |
| 17. |
*Tétreault P., Besserer-Offroy É., Murza A., Parent A., Bérubé P., René A., Dubuc I., Longpré J.M., Beaudet N., Leduc R., Marsault É., Martinez J., Cavelier F. and Sarret P. |
|
Analgesic potency of a new neurotensin analog in different experimental pain models |
|
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada. |
| 16. |
*Lavenus S., Sainsily X., Simard É., Besserer-Offroy É., Grandbois M. and Leduc R. |
|
Profiling of AT1 and UII signaling using surface plasmon resonance as a cell-based label-free approach |
|
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada. |
| 15. |
*Marsault E., Murza, A., Besserer-Offroy É., Bérubé P., Longpré J.M. and Sarret P. |
|
Deciphering the structure-function of apelin with unnatural amino acids and macrocycles. |
|
33rd European Peptide Symposium; September 1st-5th, 2014; Sofia, Bulgary. |
| 14. |
*Murza A., Besserer-Offroy É., Bérubé P., Parent A., Longpré J.M., Leduc R., Sarret P. and Marsault E. |
|
Design, Synthesis and Structure-Activity Relationship Studies of New Macrocyclic Analogs of Apelin-13 |
|
97th Canadian Chemistry Conference and Exhibition; June 1st-5th, 2014; Vancouver, Canada. |
|
[Online Abstract] |
| 13. |
*Besserer-Offroy É., Tétreault P., Lafrance M., Murza A., René A., Longpré J.M., Cavelier F., Matinez J., Marsault E., Leduc R. and Sarret P. |
|
Deciphering the NTS1 receptor signaling pathways leading to analgesia and hypothermia |
|
Neurosciences 2013 (43rd annual meeting of the Society for Neuroscience) November 9th-13th, 2013; San Diego, CA, USA. |
|
[Online Abstract] |
| 12. |
*Murza A., Besserer-Offroy É., Lafrance M., Beaudet N., Longpré J.M., Leduc R., Marsault E. and Sarret P. |
|
Incorporation of unnatural amino acids into the C-terminal of apelin-13 : Influence on binding, biased signaling and receptor functions |
|
Neurosciences 2013 (43rd annual meeting of the Society for Neuroscience) November 9th-13th, 2013; San Diego, CA, USA. |
|
[Online Abstract] |
| 11. |
*Lafrance M., Murza A., Besserer-Offroy É., Longpré J.M., Leduc R., Stroh T., Marsault E., Sarret P. |
|
Impact of the incorporation of unnatural amino acids at the C-terminal end of the Apelin peptide on pain inhibition |
|
8th European Federation of IASP Chapters (EFIC), October 9th-12th, 2013; Florence, Italia. |
|
[Online Abstract Booklet] |
| 10. |
*Besserer-Offroy É., Demeule M., Beaudet N., Régina A., Tétreault P., Belleville K., Ché C., Larocque A., Lachowicz J., Castaigne J.P., Sarret P. |
|
Use of peptide technology for analgesic brain delivery |
|
23rd American Peptide Symposium; June 22nd-23rd, 2013; Waikoloa, Hawaii, USA. |
|
[Online Abstract Booklet] |
| 9. |
*Besserer-Offroy É., Tétreault P., Lafrance M., Murza A., René A., Longpré J.M., Cavelier F., Martinez J., Marsault É., Leduc R. and Sarret P. |
|
Deciphering the NTS1 receptor signalling pathways leading to analgesia and hypothermia |
|
XXVIIth GEPROM Symposium; June 12th-13th, 2013; Montréal, Canada. |
| 8. |
*Murza A., Besserer-Offroy É., Lafrance M., Parent A., Beaudet N., Leduc R., Sarret P. and Marsault E. |
|
Incorporation of unnatural amino acids in Apelin: influence on biased signaling and activity in animal models of pain |
|
96th Canadian Chemistry Conference and Exhibition; May 26th-30th, 2013; Québec, Canada. |
|
[Online Abstract] |
| 7. |
*Tétreault P., Parent A., Besserer-Offroy É., Murza A., René A., Dubuc I., Beaudet N., Leduc R., Marsault E., Martinez J. Cavelier F. and Sarret P. |
|
Neurotensin receptor-based therapy: Achieving analgesia without opioid-related side effects |
|
Neuroscience 2012 (42nd Annual meeting of the Society for Neuroscience), October 13th-17th, 2012; New Orleans, USA. |
|
[Online Abstract] |
| 6. |
*Murza A., Parent A., Besserer-Offroy É., Tremblay H., Karadereye F., Beaudet N., Leduc R., Sarret P. and Marsault E. |
|
Structure/activity relationship and plasma stability studies of apelin’s peptide analogues |
|
32nd European Peptide Symposium; September 2nd-7th, 2012; Athens, Greece. |
| 5. |
*Lafrance M., Murza A., Besserer-Offroy É., Bossé S., Beaudet N., Leduc R., Stroh T., Marsault E. and Sarret P. |
|
Analgesic effect of Apelin and structural analogs on pain modulation |
|
14th World Congress on Pain (IASP); August 27th-31st, 2012; Milan, Italy. |
| 4. |
*Tétreault P., Parent A., Besserer-Offroy É., Murza A., René A., Dubuc I., Beaudet N., Leduc R., Marsault E., Martinez J. Cavelier F. and Sarret P. |
|
Pain relief devoid of opioid side effects following central action of a new neurotensin analog |
|
14th World Congress on Pain (IASP); August 27th-31st, 2012; Milan, Italy. |
| 3. |
*Lafrance M., Murza A., Besserer-Offroy É., Bossé S., Beaudet N., Leduc R., Marsault É. and Sarret P. |
|
Involvement of Apelin in pain modulation |
|
Neuroscience 2011 (41st Annual meeting of the Society for Neuroscience); November 12th-16th, 2011; Washington DC, USA |
| 2. |
*Murza A., Parent A., Besserer-Offroy É., Tremblay H., Karadereye F., Beaudet N., Leduc R., Sarret P. and Marsault É. |
|
Structure activity relationship and plasma stability studies of apelin’s peptide analogues |
|
94th Canadian Chemistry Conference and Exhibition; June 5th-9th, 2011; Montréal, Canada. |
| 1. |
*Murza A., Parent A., Besserer-Offroy É., Tremblay H., Karadereye F., Beaudet N., Leduc R., Sarret P. and Marsault É. |
|
Relation structure/activité et etudes de stabilité plasmatique d’analogues peptidiques de l’Apéline |
|
79è Congrès de l’ACFAS; May 9th-13th, 2011; Sherbrooke, Canada. |